SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 6, 2009
CEL-SCI CORPORATION
------ --------------------
(Exact name of Registrant as specified in its charter)
Colorado 0-11503 84-0916344
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Blvd. #802
Vienna, VA 22182
-------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
--------------
N/A
---------------------------------------------
(Former name or former address if changed since last report)
Item 1.01 Entry Into a Material Definitive Agreement
Effective March 6, 2009 CEL-SCI Corporation entered into a licensing
agreement with Byron Biopharma LLC ("Byron") under which CEL-SCI granted Byron
an exclusive license to market and distribute CEL-SCI's cancer drug Multikine(R)
in the Republic of South Africa. CEL-SCI has existing licensing agreements for
Multikine with Teva Pharmaceuticals and Orient Europharma.
Pursuant to the agreement Byron will be responsible for registering the
product in South Africa. Once Multikine has been approved for sale, CEL-SCI will
be responsible for manufacturing the product, while Byron will be responsible
for sales in South Africa. Revenues will be divided equally between CEL-SCI and
Byron. To maintain the license Byron, among other requirements, must make
milestone payments to CEL-SCI totaling $125,000 on or before March 15, 2010.
Byron also agreed to purchase shares of common stock and warrants from CEL-SCI
for $750,000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 12, 2009
CEL-SCI CORPORATION
By: /s/ Geert R. Kersten
-----------------------------------------
Geert R. Kersten, Chief Executive Officer